One or two out of every thousand babies are born with duct-dependent congenital heart disease, a life-threatening condition where the normal connection between the heart and either the lungs or the aorta is missing. When the ductus arteriosus, a blood vessel that is open only in the foetus, gradually closes in the days after delivery, the flow of blood to the lungs or the aorta is cut off, resulting in circulatory collapse.
Most of these heart defects can be corrected by one or more operations, but many of the children do not have an audible heart murmur and they are rarely detected by the standard pre-discharge medical examination.
It is estimated that a third of all newborns with duct-dependent congenital heart disease therefore leave hospital without their critical defect being discovered, and there is a risk of this number rising as the average stay in hospital grows ever shorter.
Between 2004 and 2009, researchers at the Sahlgrenska Academy lead by professor Ingegerd Östman-Smith managed to develop a simple test where sensors on the baby’s right hand and either foot are used to check the blood’s oxygen saturation.
This test, known as pulse oximetry screening, takes only a couple of minutes and can be carried out by a midwife. When tested on 40,000 newborns in West Götaland, 92% of cases of duct-dependent congenital heart disease were detected.
The study from the Sahlgrenska Academy has made a major impact internationally after being published in the highly respected British Medical Journal. All newborns in Beijing are already being screened, and Anne de-Wahl Granelli, who based her thesis on the method, has been invited to Washington, Singapore, Vietnam and Argentina to present the results during the past year.
Last week the US Secretary of Health decided to recommend that all babies born in the US should be screened using the Swedish protocol before leaving hospital. Several counties in Sweden have also introduced the test, although there is not yet any coordinated national recommendation.
“People around the world are now talking about ‘the Swedish study’, and I’ve been invited to Nanjing in China to help start up a screening programme there this autumn,” says de-Wahl Granelli.
“I’m absolutely delighted that the research has had such an impact. My colleagues and everyone else who helped us with the clinical side of the study over a three-and-a-half-year period all deserve a share of the credit for the attention it has been given worldwide.”